Indian Drug Major Sun Pharma Settles Patent Litigation With Acorda Therapeutics

Indian drug major Sun Pharma has settled a patent litigation with US-based Acorda Therapeutics over Ampyra extended-release tablets.

Sun Pharma, a multinational pharmaceutical company headquartered in Mumbai, Maharashtra, has settled a patent litigation with US-based Acorda Therapeutics Inc over Ampyra extended-release tablets, which is used in the treatment of multiple sclerosis patients.

As per the settlement the Indian drug major can launch its generic version of the medicine in the US by 2027.

Uttar Pradesh Government Contemplates Special Initiatives for Pharma Sector
We are seriously considering facilitative provisions for pharma and drugs industry, said the principal secretary of the state industrial development department.

"The company, along with its subsidiary has entered into a settlement agreement with Acorda Therapeutics Inc to resolve the pending patent litigation involving Ampyra extended release tablets in the US," Sun Pharmaceutical Industries said in a regulatory filing.

Ampyra is used to improve walking in patients with multiple sclerosis (MS).

The litigation was filed by Acorda Therapeutics in the US District Court of Delaware in response to Sun Pharma's submission of an Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration, seeking marketing approval for a generic version of Ampyra.

Indian Pharma Receives USFDA Approval For Anti-Psychotic Drugs
Aripiprazole tablets are atypical antipsychotic indicated in the treatment symptoms of psychotic conditions such as schizophrenia and bipolar disorder.

"As a result of the settlement agreement, Sun Pharma will be permitted to market a generic version of Ampyra in the US at a specified date in 2027, or potentially earlier under certain circumstances," the company said.

Details of the settlement are confidential, and the parties will submit the agreement to the Federal Trade Commission and the Department of Justice, as required by federal law, it added.

Competition Commission of India Extends Deadline for Bids to Conduct Pharma Study
Entities interested in conducting baseline study in the pharma sector and healthcare delivery system in NCR region can now submit their bids till November 5.

As per IMS MAT July 2015 sales data, Ampyra recorded annual sales of around $325 million in the US.

Sun Pharma shares today ended at Rs 888.85 apiece on the BSE, down 1.43 percent from previous close.

Indian Government Decides to Assess the Impact of FDI in Pharma Companies
A report of the Parliamentary Standing Committee on Commerce had suggested that a study group be set up to investigate the effect of FDI in brownfield pharma or operational firms.

Source-PTI